The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Effect of Minocycline on Activation of Glia and Nuclear Factor kappa B in an Animal Nerve Injury Model

  • Gu, Eun-Young (Department of Physiology, School of Medicine, Kyungpook National University) ;
  • Han, Hyung-Soo (Department of Physiology, School of Medicine, Kyungpook National University) ;
  • Park, Jae-Sik (Department of Physiology, School of Medicine, Kyungpook National University)
  • Published : 2004.10.21
Download PDF
⟨ Previous Next ⟩

Abstract

Glial cells are activated in neuropathy and play a key role in hyperalgesia and allodynia. This study was performed to determine whether minocycline could attenuate heat hyperalgesia and mechanical allodynia, and how glial cell activation and nuclear factor kappa B (NF-kappaB) were regulated by minocycline in a model of chronic constriction of sciatic nerve (CCl). When minocycline (50 mg/kg, oral) was daily administered from 1 day before to 9 days after ligation, heat hyperalgesia and mechanical allodynia were attenuated. Furthermore, when minocycline treatment was initiated 1 or 3 days after ligation, attenuation of the hypersensitive behavior was still robust. However, the effect of attenuation was less when minocycline was started from day 5. In order to elucidate the mechanism of pain attenuation by minocycline, we examined the changes of glia and NF-kappaB, and found that attenuated hyperalgesia and allodynia by minocycline was accompanied by reduced microglial activation. Furthermore, the number of NF-kappaB immunoreactive cells increased after CCI treatment and this increase was attenuated by minocycline. We also observed translocation of NF-kappaB into the nuclei of activated glial cells. These results suggest that minocycline inhibits activation of glial cells and NF-kappaB, thereby attenuating the development of behavioral hypersensitivity to stimuli.

Keywords

References

  1. Aldskogius H, Kozlova EN. Central neuron-glial and glia-glial interactions following axon injury. Prog Neurobiol 55: 1- 26, 1998
  2. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Nat! Acad Sci USA 93: 14014-14019, 1996
  3. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176: 1061-1068, 1980
  4. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 87: 13-20, 1996
  5. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071, 1997
  6. Bennett GJ, Xie YK. A peripheral mononeuropathy and neuropathic pain behaviors following peripheral seen in man. Pain 33: 87 -107, 1998
  7. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 18: 3251- 3260, 1998
  8. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6: 797 - 801, 2000
  9. Colburn RW, DeLeo JA, Rickman AJ, Yaeger MP, Kwon P, Hickey WF. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol 79: 163-175, 1997
  10. Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol 157: 289-304, 1999
  11. Coyle DE. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Olia 23: 75- 83, 1998
  12. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6, 2001
  13. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98: 14669-14674, 2001
  14. Eriksson NP, Persson JK, Aldskogius H, Svensson M. A quantitative analysis of the astroglial cell reaction in primary sensory termination areas following sciatic nerve injury and treatment with nerve growth factor. Exp Brain Res 114: 393- 404, 1997
  15. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 565: 1-7, 1991
  16. Gilmore SA, Sims YJ, Leiting JE. Astrocytic reactions in spinal gray matter following sciatic axotomy. Glia 3: 342-349, 1990
  17. Han HS, Yenari MA. Cellular targets of brain inflammation in stroke. Curr Opin Inuestig Drugs 4: 522-529, 2003
  18. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-kappa B activity in neurons. Mol Cell BioI 14: 3981- 3992, 1994
  19. Kreutzberg, GW. Microglia: a sensor for pathological events in the CNS, Trends Neurosci 19: 312-318, 1990
  20. Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy 1: 181-191, 2002
  21. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315: 6164, 2001
  22. Ma W, Bisby MA. Increased activation of nuclear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. Brain Res 797: 243-254, 1998
  23. Meller ST, Dysktra C, Grzybycki D, Murphy S, Gebhart GF. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33: 1471-1478, 1994
  24. Moore S, Thanos S. The concept of microglia in relation to central nervous system disease and regeneration. Prog Neurobiol 48: 441-460, 1996
  25. Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 126: 1371- 1381, 2003
  26. 0' Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20:252-258, 1997
  27. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 306: 624-630, 2003
  28. Sadowski T, Steinmeyer J. Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol 28: 336- 340, 2001
  29. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage and neurological dysfunction. Neurosurgery 48: 1393-1399, 2001
  30. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation, proliferation of microglia. J Neurosci 21: 2580- 2588, 2001a
  31. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166: 7527 - 7533, 2001
  32. Tikka T, Usenius T, Tenhunen M, Keinanen R, Koistinaho J. Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic protect neurons against apoptosis induced by ionizing radiation. J Neurochem 78: 1409-1414, 2001b
  33. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Nat! Acad Sci USA 100: 10483 -10487, 2003
  34. Watkins LR, Maier SF. GLIA: A novel drug discovery target for clinical pain. Nat Rev Drug Discov 973-985, 2003
  35. Watkins LR, Martin D, Ulrich P, Tracey K, Maier SF. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 71: 225- 235, 1997
  36. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain 93: 201- 205, 2001a
  37. Watkins LR, Milligan ED, and Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 24: 450-455, 2001b
  38. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi D, Ischiropoulos H, Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771, 2002
  39. Ye SM, Johnson RW. Increased interleukin-6 expression by microglia from brain of aged mice. J Neuroimmunol 93: 139- 148, 1990
  40. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Nat! Acad Sci USA 95: 15769-15774, 1998
  41. Zhang SC, Goetz BD, Duncan ID. Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors. Glia 41: 191-198, 2003
  42. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110, 1983